Literature DB >> 25974157

Non-steroidal anti-inflammatory drugs and the risk of head and neck cancer: A case-control analysis.

Claudia Becker1, Jessica Claire Wilson1, Susan S Jick2, Christoph R Meier1,2,3.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) and acetylsalicylic acid (aspirin) have been associated with a reduced risk for certain cancers. We explored the association between use of NSAIDs and the risk of head and neck cancer (HNC). We conducted a case-control analysis in the UK-based Clinical Practice Research Datalink (CPRD) among people below the age of 90 years with incident HNC between 1995 and 2013. Six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the CPRD prior to the HNC diagnosis. Other potential confounders including comorbidities and comedication were also evaluated, and we adjusted our final analyses for BMI, smoking and alcohol consumption. Our analyses included 2,745 HNC cases and 16,470 controls. Aspirin or NSAID use overall did not significantly change the HNC risk. However, patients with six or more prescriptions for ibuprofen were at a statistically significantly reduced risk for HNC (adjusted OR 0.59, 95% CI 0.37-0.94). The HNC risk tended to decrease with increasing cumulative exposure to ibuprofen, and to be more pronounced for cancer of the larynx. To conclude, in this large population-based observational study we found a decreased risk for HNC associated with regular use of ibuprofen.
© 2015 UICC.

Entities:  

Keywords:  NSAIDs; aspirin; case control study; epidemiology; head and neck cancer

Mesh:

Substances:

Year:  2015        PMID: 25974157     DOI: 10.1002/ijc.29601

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Gene Expression of the D-Series Resolvin Pathway Predicts Activation of Anti-Tumor Immunity and Clinical Outcomes in Head and Neck Cancer.

Authors:  Domenico Mattoscio; Giulia Ferri; Claudia Miccolo; Susanna Chiocca; Mario Romano; Antonio Recchiuti
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

2.  NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.

Authors:  Khosrow Kashfi; Mitali Chattopadhyay; Ravinder Kodela
Journal:  Redox Biol       Date:  2015-08-14       Impact factor: 11.799

3.  Nonsteroidal anti-inflammatory drugs using and risk of head and neck cancer: a dose-response meta analysis of prospective cohort studies.

Authors:  Jun Shi; Weidong Leng; Lunhua Zhao; Chenli Xu; Jue Wang; Xiaoli Chen; Yu Wang; Xingchun Peng
Journal:  Oncotarget       Date:  2017-10-05

4.  Association of nonsteroidal anti-inflammatory drugs and aspirin use and the risk of head and neck cancers: a meta-analysis of observational studies.

Authors:  Lanhua Tang; Huabin Hu; Huai Liu; Chengzhu Jian; Hui Wang; Jin Huang
Journal:  Oncotarget       Date:  2016-10-04

5.  Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies.

Authors:  Yan Qiao; Tingting Yang; Yong Gan; Wenzhen Li; Chao Wang; Yanhong Gong; Zuxun Lu
Journal:  BMC Cancer       Date:  2018-03-13       Impact factor: 4.430

6.  Association of Nonsteroidal Anti-inflammatory Drug Use With Survival in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Chemoradiation Therapy.

Authors:  Austin J Iovoli; Gregory M Hermann; Sung Jun Ma; Alexis J Platek; Mark K Farrugia; Edwin Yau; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Moni A Kuriakose; Wesley L Hicks; Anurag K Singh
Journal:  JAMA Netw Open       Date:  2020-06-01

Review 7.  NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase.

Authors:  Oluwafunke R Kolawole; Khosrow Kashfi
Journal:  Int J Mol Sci       Date:  2022-01-27       Impact factor: 5.923

8.  Antitumoral effects of γCdcPLI, a PLA2 inhibitor from Crotalus durissus collilineatus via PI3K/Akt pathway on MDA-MB-231 breast cancer cell.

Authors:  Sarah N C Gimenes; Daiana S Lopes; Patrícia T Alves; Fernanda V P V Azevedo; Lara Vecchi; Luiz R Goulart; Thais C S Rodrigues; André L Q Santos; Vera L de C Brites; Thaise L Teixeira; Cláudio V da Silva; Matheus H Dias; Samuel C Teixeira; Renata S Rodrigues; Kelly A G Yoneyama; Ricardo A Oliveira; Veridiana de M Rodrigues
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.